Abstract: Provided herein are methods for treating sickle cell disease comprising administering Compound (I), a modulator of hemoglobin, according to certain dosing regimens.

Abstract: Provided herein are methods of treating a patient infected with a coronavirus and having a baseline level of CRP below 150 mg/L, comprising administering to the patient a compound of formula 1: or a pharmaceutically-acceptable salt thereof.

Abstract: Methods of safely administrating a gut-selective JAK3 inhibitor by oral administration are described. Also described are methods for providing clinically proven safe treatment of gastrointestinal inflammatory diseases, such as celiac disease, by oral administration of a gut-selective JAK3 inhibitor.

Abstract: Methods of safely administrating a gut-selective JAK3 inhibitor by oral administration are described. Also described are methods for providing clinically proven safe treatment of gastrointestinal inflammatory diseases, such as celiac disease, by oral administration of a gut-selective JAK3 inhibitor.

Abstract: Provided herein are methods of treating a patient infected with a coronavirus comprising administering to the patient a compound of formula 1: or a pharmaceutically-acceptable salt thereof.

Abstract: Doses and methods for administering telavancin or a pharmaceutically-acceptable salt thereof to a human patient having an infection caused by Staphylococcus aureus, such as bacteremia, pneumonia, endocarditis, osteomyelitis, a prosthetic joint infection or a complicated skin and skin structure infection, are disclosed. Also disclosed are methods for treating an infection caused by Staphylococcus aureus in a human patient using telavancin or a pharmaceutically-acceptable salt thereof. The dose of telavancin administered to the patient is determined, in part, by the weight and creatinine clearance of the patient.

Abstract: Doses and methods for administering telavancin or a pharmaceutically-acceptable salt thereof to a human patient having an infection caused by Staphylococcus aureus, such as bacteremia, pneumonia, endocarditis, osteomyelitis, a prosthetic joint infection or a complicated skin and skin structure infection, are disclosed. Also disclosed are methods for treating an infection caused by Staphylococcus aureus in a human patient using telavancin or a pharmaceutically-acceptable salt thereof. The dose of telavancin administered to the patient is determined, in part, by the weight and creatinine clearance of the patient.

Abstract: Doses and methods for administering telavancin or a pharmaceutically-acceptable salt thereof to a human patient having an infection caused by Staphylococcus aureus, such as bacteremia, pneumonia, endocarditis, osteomyelitis, a prosthetic joint infection or a complicated skin and skin structure infection, are disclosed. Also disclosed are methods for treating an infection caused by Staphylococcus aureus in a human patient using telavancin or a pharmaceutically-acceptable salt thereof. The dose of telavancin administered to the patient is determined, in part, by the weight and creatinine clearance of the patient.

Abstract: The invention encompasses novel computer models of atherosclerosis and systems for predicting development and progression of atherosclerosis as well as associated cardiovascular risk. In particular, the computer model of atherosclerosis comprises a) a cholesterol metabolism module; b) an atherogenesis module; and c) a plaque stability module. The computer model optionally further comprises a cardiovascular risk module.

Abstract: The invention provides a souvenir travel guidebook with an ability to have holding members on the same page of a printed material to be utilized for displaying traditional photographs, for storing mounted or unmounted slide transparencies of varying sizes, picture/photo CD's, floppy disks, postcards, tickets and other travel memorabilia. It is a new method to display and organize the above items in such a way that the souvenir travel guidebook itself is also the photo album.